Hopp til hovedinnhold

TIA - "drypp"

TIA eller "drypp" er et forbigående anfall av nedsatt blodforsyning til deler av hjernen. TIA-anfallene har rask start og kort varighet. Etter dryppet vender kroppen tilbake til normal funksjon.

Sist revidert:

QR
Del pasientinformasjon

Den ligger åpent tilgjengelig på NHI.no sammen annen relevant informasjon

https://nhi.no/sykdommer/hjernenervesystem/hjerneslag-og-blodninger/tia-drypp/ 

Drypp, symptomer og tegn

Drypp, årsaker

Drypp, risikofaktorer

Drypp, når bør du søke hjelp?

Drypp, diagnostikk

Drypp, behandling

Drypp, forebygging

Vil du vite mer?

Kilder

Referanser

Dette dokumentet er basert på det profesjonelle dokumentet Hjerneslag og TIA. Referanselisten for dette dokumentet vises nedenfor.

  1. Indredavik B. Embolier som årsak til hjerneslag. Tidsskr Nor Legeforen 2001; 121: 2142. Tidsskrift for Den norske legeforening 
  2. Folkehelseinstituttet. Hjerte- og karregisteret. Forekomst av hjerte- og karsykdom i 2020. Siden lest 28.10.2021 www.fhi.no 
  3. Rafay MF, Pontigon A-M, Chiang J, et al. Delay to diagnosis in acute pediatric arterial ischemic stroke. Stroke 2009; 40: 58-64. Stroke 
  4. Wyller TB, Bautz-Holter E, Holmen J. Prevalence of stroke and stroke-related disability in North Trøndelag county, Norway. Cerebrovasc Dis 1994; 4: 421-427. PubMed 
  5. The GBD 2016 Lifetime Risk of Stroke Collaborators. Global, Regional, and Country-Specific Lifetime Risks of Stroke, 1990 and 2016. N Engl J Med 2018; 379: 2429-37. doi:10.1056/NEJMoa1804492 DOI 
  6. Folkehelseinstituttet. Dødsfall etter hjerteinfarkt og hjerneslag er dramatisk redusert. Dødsårsaksregisteret. Publisert 04.12.2019 www.fhi.no 
  7. Sposato LA, Cipriano LE, Saposnik G, Ruíz Vargas E, Riccio PM, Hachinski V. Diagnosis of atrial fibrillation after stroke and transient ischaemic attack: a systematic review and meta-analysis. Lancet Neurol. 2015 Apr;14(4):377-87 . pmid:25748102 PubMed 
  8. Gladstone DJ, Spring M, Dorian P, et al. Atrial fibrillation in patients with cryptogenic stroke. N Engl J Med. 2014; 370: 2467-77. doi: 10.1056/NEJMoa1311376 DOI 
  9. Connolly ES Jr, Rabinstein AA, Carhuapoma JR, et al.; American Heart Assoication Stroke Council; Council on Cardiovascular Radiology and Intervention; Couincil on Cardiovascular Nursing; Council on Cardiovascular Surgery and Anesthesia; Council on Clinical Cardiology. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2012;43(6):1711–1737.
  10. Solbakken T, Moen G, Tysnes O-B. Kraniocervikal arteriedisseksjon. Tidsskr Nor Lægeforen 2002; 122: 2355-7. PubMed 
  11. Sandvik L, Erikssen J, Thaulow E, Erikssen G, Mundal R, Rodahl K. Physical fitness as a predictor of mortality among healthy, middle-aged Norwegian men. N Engl J Med 1993; 328: 533 - 7. New England Journal of Medicine 
  12. Helsedirektoratet. Nasjonal faglig retningslinje for behandling og rehabilitering ved hjerneslag. Oslo, Helsedirektoratet. Sist oppdatert 27.04.2020. helsedirektoratet.no 
  13. Easton JD, Albers GW, Caplan LR, et al. Discussion: Reconsideration of TIA terminology and definitions. Neurology. 2004; 62: 29-34. PubMed 
  14. O'Donnell MJ, Xavier D, Liu L, et al. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case control study. Lancet 2010; 376: 112-23. PubMed 
  15. Pan A, Sun Q, Okereke OI, et al. Depression and risk of stroke morbidity and mortality: a meta-analysis and systematic review. JAMA 2011; 306: 1241-9. Journal of the American Medical Association 
  16. Kernan WN, Viscoli CM, Brass LM, Broderick JP et al. Phenylpropanolamine and the risk of hemorrhagic stroke. N Engl J Med 2000; 343: 1826-32. New England Journal of Medicine 
  17. Schmidt M, Hováth-Puhó E, Christiansen CF, et al. Preadmission use of non-aspirin nonsteroidal anti-inflammatory drugs and 30-day stroke mortality. Neurology 2014; 83: 2013-22. doi:10.1212/WNL.0000000000001024 DOI 
  18. Bénard-Laribière A, Hucyeau E, Debette S, et al. Risk of first ischaemic stroke and use of antidopaminergic antiemetics: nationwide case-time-control study. BMJ 2022; 376: e066192. pmid:35321876 PubMed 
  19. Cleary P, Shorvon S, Tallis R. Late-onset seizures as a predictor of subsequent stroke. Lancet 2004; 363: 1184-6. PubMed 
  20. Demel SL, Kittner S, Ley SH, et al. Stroke Risk Factors Unique to Women. Stroke 2018; 49: 518-23. pmid:29438077 PubMed 
  21. Lidegaard Ø, Løkkegaard E, Jensen A, Skovlund CW, Keiding N. Thrombotic stroke and myocardial infarction with hormonal contraception. N Engl J Med 2012; 366: 2257-66. New England Journal of Medicine 
  22. Smeeth L, Thomas SL, Hall AJ et al. Risk of myocardial infarction and stroke after acute infection and vaccination. N Engl J Med 2004; 351: 2611-8. New England Journal of Medicine 
  23. Minassian C, D'Aiuto F, Hingorani AD, Smeeth L. Invasive dental treatment and risk for vascular events: a self-controlled case series. Ann Intern Med 2010; 153: 499-506. PubMed 
  24. Strazzulo P, D'Elia L, Kandala N-B, Cappuccio FP. Salt intake, stroke, and cardiovascular disease: a meta-analysis of prospective studies. BMJ 2009; 339: b4567. BMJ (DOI) 
  25. Haynes MJ, Vincent K, Fischhoff C, et al. Assessing the risk of stroke from neck manipulation: a systematic review. Int J Clin Pract 2012; 66: 940-7. PubMed 
  26. Kerkhoff G. Neurovisual rehabilitation: recent developments and future directions. J Neurol Neurosurg Psychiatry 2000; 68: 691-706. PubMed 
  27. Shahjouei S, Li J, Koza E, et al. Risk of Subsequent Stroke Among Patients Receiving Outpatient vs Inpatient Care for Transient Ischemic Attack A Systematic Review and Meta-analysis. JAMA Netw Open 2022. doi:10.1001/jamanetworkopen.2021.36644 DOI 
  28. Kiyohara T, Kamouchi M, Kumai Y, et al. ABCD3 and ABCD3-I scores are superior to ABCD2 score in the prediction of short- and long-term risks of stroke after transient ischemic attack. Stroke 2014; 45: 418-25. pmid:24335223 PubMed 
  29. Perry JJ, Sivilotti MLA, Émond M, et al. CCBYNC Open access Research Prospective validation of Canadian TIA Score and comparison with ABCD2 and ABCD2i for subsequent stroke risk after transient ischaemic attack: multicentre prospective cohort study. BMJ 2021; 372: n49. pmid:33541890 PubMed 
  30. Stroke Unit Trialists' Collaboration.Organised inpatient (stroke unit) care for stroke. Cochrane Database Syst Rev. 2013 Sep 11;9:CD000197. doi: 10.1002/14651858.CD000197.pub3. The Cochrane Library 
  31. Indredavik B, Fjærtoft H, Ekeberg G, Løge A, Mørch B. Benefit of an extended stroke unit service with early supported discharge. A randomized controlled trial. Stroke 2000; 31: 2989-94. PubMed 
  32. Siemieniuk RAC, Chu DK, Kim LH, et al. Oxygen therapy for acutely ill medical patients: a clinical practice guideline. BMJ 2018; 363: k4169. pmid:30355567 PubMed 
  33. Prabhakaran S, Ruff I, Bernstein RA. Acute stroke intervention: a systematic review. JAMA. 2015; 313:1451-62. doi: 10.1001/jama.2015.3058 DOI 
  34. Wardlaw JM, Murray V, Berge E, et al.Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev. 2014 ;7:CD000213. doi: 10.1002/14651858.CD000213.pub3. The Cochrane Library 
  35. Smedslund G, Myrhaug HT, Hov L, Kirkehei I. Effekt av trombolytisk behandling i intervallet 3 til 4,5 timer etter hjerneslag. Rapport fra Folkehelseinstituttet – 2016. ISBN 978-82-8082-746-3 www.kunnskapssenteret.no 
  36. Lees KR, Bluhmki E, von Kummer R, et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 2010; 375: 1695-703. PubMed 
  37. Ahmed N, Wahlgren N, Grond M, et al. Implementation and outcome of thrombolysis with alteplase 3-4,5 h after an acute stroke: an updated analysis from SITS-ISTR. Lancet Neurol 2010; 9: 866-74. PubMed 
  38. Strbian D, Ringleb P, Michel P, et al. Ultra-early intravenous stroke thrombolysis. Stroke 2013. doi: 10.1161/​STROKEAHA.111.000819
  39. The IST-3 collaborative group. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial (IST-3)): a randomised controlled trial. Lancet 2012; 379: 2352-63. PubMed 
  40. Berkhemer OA, Fransen PSS, van den Berg LA, et al. A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med 2014. doi:10.1056/NEJMoa1411587 DOI 
  41. Powers WJ, Derdeyn CP, Biller J, et al. 2015 AHA/ASA focused update of the 2013 guidelines for the early management of patients with acute ischemic stroke regarding endovascular treatment. Stroke 2015. doi:10.1161/STR.0000000000000074 DOI 
  42. Goyal M, Demchuk AM, Menon BK, et al for the ESCAPE Trial Investigators. Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med 2015. doi:10.1056/NEJMoa1414905 DOI 
  43. Campbell BCV, MitchellPJ, Kleinig TJ, et al for the EXTEND-IA Investigators. Endovascular therapy for ischemic stroke with perfusion-imaging selection. N Engl J Med 2015. doi:10.1056/NEJMoa1414792 DOI 
  44. Saver J, Goyal M, Bonafe A, et al for the SWUFT PRIME Investigators. Primary results. Nashville, february 2015.
  45. Jovin TG, Chamorro A, Cobo E, et al. Thrombectomy within 8 hours after symptom onset in ischemic stroke. N Engl J Med 2015. doi:DOI: 10.1056/NEJMoa1503780 DOI 
  46. Albers GW, Marks MP, Kemp S, et al. Thrombectomy for Stroke at 6 to 16 Hours with Selection by Perfusion Imaging. New Engl J Med 2018. pmid:29364767 PubMed 
  47. National Institute for Health and Care Excellence. Stroke and transient ischaemic attack in over 16s: diagnosis and initial management—draft for consultation. Nov 2018. www.nice.org.uk 
  48. Nogueira RG, Jadhav AP, Haussen DC, et al. Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct. N Engl J Med 2018; 378: 11-21. pmid:29129157 PubMed 
  49. Jovin TG, Nogueira RG, Lansberg MG, et al. Thrombectomy for anterior circulation stroke beyond 6 h from time last known well (AURORA): a systematic review and individual patient data meta-analysis. Lancet 2022; 399: 249-58. pmid:34774198 PubMed 
  50. Liu N, Cadilhac DA, Andrew NE, et al. Randomized controlled trial of early rehabilitation after intracerebral hemorrhage stroke: difference in outcomes within 6 months of stroke. Stroke. 2014 Dec;45(12):3502-7. PubMed 
  51. Legg LA, Drummond AE, Langhorne P. Occupational therapy for patients with problems in activities of daily living after stroke. Cochrane Database of Systematic Reviews 2006: 4: CD003585. doi:10.1002/14651858.CD003585.pub2. The Cochrane Library 
  52. Næss H, Waje-Andreassen U, Thomassen L. Overvåking ved akutt hjerneinfarkt. Tidsskr Nor Lægeforen 2006; 126: 444-6. PubMed 
  53. Ryu W-S, Schellingerhout D, Hong K-S, et al. Relation of Pre-Stroke Aspirin Use With Cerebral Infarct Volume and Functional Outcomes. Ann Neurol 2021; 90: 763-76. pmid:34536234 PubMed 
  54. Adams H jr, Adams RJ, Brott T, et al. Guidelines for the early management of patients with ischemic stroke. a scientific statement from the Stroke Council of The American Stroke Association. Stroke 2003; 34: 1056-83. PubMed 
  55. Vandvik PO, Kristiansen A, Brandt L, Berge E, Dahm AE, Halvorsen S, Sandset PM. Retningslinje for antitrombotisk behandling og tromboseprofylakse, 2013. http://www.magicapp.org/guideline/1
  56. Olesen JB, Lip GYH, Hansen ML, et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study . BMJ 2011; 342: d124. BMJ (DOI) 
  57. Hobbs FD, Roalfe AK, Lip GY, et al. Performance of stroke risk scores in older people with atrial fibrillation not taking warfarin: comparative cohort study from BAFTA trial. BMJ 2011; 342: d3653. BMJ (DOI) 
  58. Turan TN, Nizam A, Lynn MJ, et al. Relationship between risk factor control and vascular events in the SAMMPRIS trial. Neurology 2016. pmid:28003500 PubMed 
  59. Friberg L, Skeppholm M, Terènt M. Benefit of anticoagulation unlikely in patients with atrial fibrillation and a CHA2DS2-VASc score of 1. J Am Coll Cardiol 2015: 27; 65:225. PMID: 25614418 PubMed 
  60. Hernandez I, He M, Brooks MM, et al. Adherence to Anticoagulation and Risk of Stroke Among Medicare Beneficiaries Newly Diagnosed with Atrial Fibrillation. Am J Cardiovasc Drugs 2019. PMID: 31523759 PubMed 
  61. Gynnild MN, Hageman SHJ, Dorrestreijn JAN, Spigset O, et al. Risk Stratification in Patients with Ischemic Stroke and Residual Cardiovascular Risk with Current Secondary Prevention. Clin Epidemiol 2021; 13: 813-23. pmid:34566434 PubMed 
  62. Russell D, Lund C, Dahl A. Sekundærprofylakse etter hjerneinfarkt og transitorisk iskemisk anfall. Tidsskr Nor Lægeforen 2007; 127: 1379-82. PubMed 
  63. Kwok CS, Shoamanesh A, Copley HC, et al. Efficacy of antiplatelet therapy in secondary prevention following lacunar stroke: pooled analysis of randomized trials. Stroke 2015; 46: 1014-23. doi:10.1161/STROKEAHA.114.008422 DOI 
  64. Greving JP, Diener HC, Reitsma JB, et al. Antiplatelet Therapy After Noncardioembolic Stroke. Stroke. 2019 Jul;50(7):1812-18. PMID: 31177983 PubMed 
  65. Diener HC, Sacco RL, Easton JD, et al. Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source. N Engl J Med. 2019 May 16;380(20):1906-1917. doi: 10.1056/NEJMoa1813959 DOI 
  66. Hart RG, Sharma M, Mundl H, et al. Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source. N Engl J Med 2018; 378: 2191-201. pmid:29766772 PubMed 
  67. RESTART Collaboration. Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial. Lancet 2019. doi:10.1016/S0140-6736(19)30840-2 DOI 
  68. Amarenco P, Kim JS, Labreuche J, et al. A Comparison of Two LDL Cholesterol Targets after Ischemic Stroke. N Engl J Med 2019. pmid:31738483 PubMed 
  69. Giugliano RP, Pedersen TR, Saver JL, et al; FOURIER Investigators. Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis. Stroke. 2020 May;51(5):1546-1554. doi: 10.1161/STROKEAHA.119.027759. Epub 2020 Apr 21. PMID: 32312223.
  70. FOCUS Trial Collaboration. Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial.. Lancet 2018. doi:10.1016/S0140-6736(18)32823-X DOI 
  71. Legg LA, Tilney R, Hsieh CF, et al. Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery. Cochrane Database Syst Rev. 2019 Nov 26;2019(11). doi: 10.1002/14651858.CD009286.pub3 DOI 
  72. Snaphaan L, de Leeuw FE. Poststroke memory function in nondemented patients: a systematic review on frequency and neuroimaging correlates. Stroke 2007; 38: 198-203. PubMed 
  73. Pettersen R. Inkontinens etter hjerneslag. Tidsskr Nor Lægeforen 2007; 127: 1383-6. PubMed 
  74. The CLOTS Trials Collaboration. Effectivness of thigh-length graduated compression stockings to reduce the risk of deep vein thrombosis after stroke (CLOTS trial 1): a multicentre, randomised controlled trial. Lancet 2009; 373: 1958-65. PubMed 
  75. Levine DA, Galecki AT, Langa KM, et al. Trajectory of cognitive decline after incident stroke. JAMA 2015; 314: 41-51. doi:10.1001/jama.2015.6968 DOI 
  76. Fure B. Depresjon, angst og andre emosjonelle symptomer ved hjerneslag. Tidsskr Nor Lægeforen 2007; 127: 1387-9. PubMed 
  77. Robinson RG, Jorge RE, Moser DJ et al. Escitalopram and Problem-Solving Therapy for Prevention of Poststroke Depression. JAMA 2008; 299: 2391-2400. PubMed 
  78. Jones JS, Kimata R, Almeida OP, et al. Risk of Fractures in Stroke Patients Treated With a Selective Serotonin Reuptake Inhibitor: A Systematic Review and Meta-Analysis. Stroke 2021. PMID: 34167325 PubMed 
  79. Oldenbeuving AW, de Kort PL, Jansen BP, et al. Delirium in the acute phase after stroke: Incidence, risk factors, and outcome. Neurology 2011; 76: 993-9. Neurology 
  80. Engstad T, Viitanen Matti, Almkvist O. Kognitiv svikt etter hjerneslag - diagnostikk og håndtering. Tidsskr Nor Lægeforen 2007; 127: 1390-3. PubMed 
  81. Pendlebury ST, Rothwell PM, Oxford Vascular Study. Incidence and prevalence of dementia associated with transient ischaemic attack and stroke: analysis of the population-based Oxford Vascular Study. Lancet Neurol 2019; 18: 248-58. pmid:30784556 PubMed 
  82. Fjærtoft H, Indredavik B. Kostnadsvurderinger ved hjerneslag Tidsskr Nor Lægeforen 2007; 127: 744 - 7. PubMed 
  83. Toyoda K, Yoshimura S, Nakai M, et al. Twenty-Year Change in Severity and Outcome of Ischemic and Hemorrhagic Strokes. JAMA Neurol 2022; 79: 61-69. pmid:34870689 PubMed 
  84. Folkehelseinstituttet. Kvalitet i helsetjenesten. 30 dagers overlevelse og reinnleggelse etter sykehusinnleggelse. Resultater for 2019. FHI 2020. www.fhi.no 
  85. Skajaa N, Adelborg K, Horváth-Puhó E, et al. Risks of Stroke Recurrence and Mortality After First and Recurrent Strokes in Denmark: A Nationwide Registry Study. Neurology 2021. pmid:34845054 PubMed 
  86. Drummond AE, Pearson B, Lincoln NB, Berman P. Ten year follow-up of a randomised controlled trial of care in a stroke rehabilitation unit. BMJ 2005; 331: 491-2. PubMed 
  87. Helsedirektoratet. Pakkeforløp for hjerneslag. Sist faglig oppdatert 23.12.2020. Siden lest 28.10.2021 www.helsedirektoratet.no 
  88. Lossius MI, Rønning OM, Gjerstad L. Epilepsi etter hjerneslag. Tidsskr Nor Lægeforen 2004; 124: 620-2. PubMed